Kailera (Nasdaq: KLRA) closed its initial public offering on April 20, 2026, selling 44,921,875 common shares at $16.00 per share, including full exercise of the underwriters' option for 5,859,375 additional shares.
The aggregate gross proceeds were $718.8 million before underwriting discounts, commissions and offering expenses; Kailera's common stock is listed on the Nasdaq Global Select Market under the ticker KLRA.
Shares listed on Nasdaq Global Select Market under ticker KLRA
Negative
Offering subject to underwriting discounts and commissions that reduce net proceeds
Issuance of 44,921,875 new common shares increases outstanding share count and may dilute existing holders
News Market Reaction – KLRA
+2.48%
16 alerts
+2.48%Session close to close
+14.3%Peak Tracked
-4.1%Trough Tracked
$3.33BMarket Cap
0.1xRel. Volume
In the Apr 21 session, KLRA gained 2.48%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +14.3% during that session.
Argus tracked a trough of -4.1% from its starting point during tracking.
Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
This announcement confirms completion of Kailera’s IPO, with 44,921,875 shares sold at $16.00 per sh...
Analysis
This announcement confirms completion of Kailera’s IPO, with 44,921,875 shares sold at $16.00 per share for gross proceeds of $718.8 million. The registration statement on Form S-1 became effective on April 16, 2026, and shares trade on the Nasdaq Global Select Market under ticker KLRA. Investors may track how the expanded share count trades within the $23.70–$27.50 range and how liquidity develops following the offering.
Key Figures
IPO shares offered:44,921,875 sharesUnderwriters’ option shares:5,859,375 sharesIPO price:$16.00 per share+5 more
8 metrics
IPO shares offered44,921,875 sharesInitial public offering total share count
Underwriters’ option shares5,859,375 sharesAdditional shares from full exercise of underwriters’ option
IPO price$16.00 per shareInitial public offering price
Gross IPO proceeds$718.8 millionAggregate gross proceeds before fees and expenses
S-1 file numberFile No. 333-294690Registration statement identifier with the SEC
S-1 effective dateApril 16, 2026Date registration statement became effective
Current price$26.00Price prior to/around IPO closing news
52-week range$23.70–$27.50Pre-news 52-week low and high
Key Terms
initial public offering, underwriters’ option, form s-1, prospectus, +1 more
5 terms
initial public offeringfinancial
"announced the closing of its initial public offering of 44,921,875 shares"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
underwriters’ optionfinancial
"includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares"
An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.
form s-1regulatory
"A registration statement on Form S-1 (File No. 333-294690) relating to the offering"
A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.
prospectusregulatory
"A prospectus relating to and describing the terms of the offering has been filed with the SEC"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
nasdaq global select markettechnical
"Kailera’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “KLRA.”"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share. All of the shares of common stock were offered by Kailera. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $718.8 million. Kailera’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “KLRA.”
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI acted as joint book-running managers for the offering. William Blair acted as lead manager for the offering.
A registration statement on Form S-1 (File No. 333-294690) relating to the offering has been filed with the Securities and Exchange Commission (SEC) and became effective on April 16, 2026. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact
Maura Gavaghan Vice President, Corporate Communications and Investor Relations maura.gavaghan@kailera.com
FAQ
How many shares did Kailera (KLRA) sell in its April 20, 2026 IPO?
Kailera sold 44,921,875 common shares in the IPO, including the underwriters' full exercise. According to Kailera, that total includes 5,859,375 additional shares sold under the option to purchase extra shares.
What was the IPO price per share for Kailera (KLRA) on April 20, 2026?
The initial public offering price was $16.00 per share. According to Kailera, that price produced aggregate gross proceeds of $718.8 million before underwriting discounts and offering expenses.
How much did Kailera (KLRA) raise in gross proceeds from its IPO?
Kailera raised $718.8 million in aggregate gross proceeds before fees. According to Kailera, this figure is before deducting underwriting discounts, commissions and other offering expenses.
On which exchange is Kailera (KLRA) listed after the April 20, 2026 IPO?
Kailera's common stock is listed on the Nasdaq Global Select Market under the ticker KLRA. According to Kailera, trading will occur under that symbol following the offering.
Who served as joint book‑running managers for Kailera's (KLRA) April 2026 IPO?
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI served as joint book‑running managers. According to Kailera, William Blair acted as lead manager for the offering.
